Answers are grounded in this paper and cite their sources.
This guide outlines management strategies and drug interventions for immunoglobulin A nephropathy, indicating critical treatment pathways.
This guide outlines up-to-date approaches to identifying, managing and modifying the underlying drivers of immunoglobulin A nephropathy, a progressive immune-mediated kidney disease, including the role of targeted-release budesonide.
No takes yet. Share an insight, caveat, or question.
Barratt et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: